Loading…
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-189M | $-168M | $-144M | -32.1% | - | - |
| 2024 | $0M | $-157M | $-134M | $-110M | -29.1% | - | - |
| 2023 | $0M | $-113M | $-100M | $-98M | -31.4% | - | - |
| 2022 | $0M | $-71M | $-68M | $-58M | -19.5% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 71.66 | 114.36 | 158.83 | 191.41 |
| Operating Income | -71.66 | -114.36 | -158.83 | -191.41 |
| EBITDA | -71.12 | -112.62 | -156.54 | -189.14 |
| EBIT | -71.66 | -114.36 | -158.83 | -191.41 |
| Pretax Income | -67.64 | -100.16 | -133.81 | -167.79 |
| Net Income | -67.64 | -100.16 | -133.81 | -167.79 |
| Net Income Common Stockholders | -67.64 | -100.16 | -133.81 | -167.79 |
| Total Expenses | 71.66 | 114.36 | 158.83 | 191.41 |
| Interest Income | 4.02 | 14.19 | 25.02 | 23.61 |
| Research And Development | 54.03 | 90.91 | 126.97 | 151.39 |
| Selling General And Administration | 17.63 | 23.45 | 31.87 | 40.02 |
| Normalized EBITDA | -71.12 | -112.62 | -156.54 | -189.14 |
| Normalized Income | -67.64 | -100.16 | -133.81 | -167.79 |
| Basic EPS | -0.31 | -1.57 | -0.42 | 0 |
| Diluted EPS | -0.31 | -1.57 | -0.42 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -67.64 | -100.16 | -133.81 | -167.79 |
| Reconciled Depreciation | 0.54 | 1.73 | 2.29 | 2.27 |
| Net Interest Income | 4.02 | 14.19 | 25.02 | 23.61 |
| Net Income From Continuing And Discontinued Operation | -67.64 | -100.16 | -133.81 | -167.79 |
| Total Operating Income As Reported | -71.66 | -114.36 | -158.83 | -191.41 |
| Diluted Average Shares | 63.23 | 63.72 | 94.72 | 0 |
| Basic Average Shares | 63.23 | 63.72 | 94.72 | 0 |
| Diluted NI Availto Com Stockholders | -67.64 | -100.16 | -133.81 | -167.79 |
| Net Income Including Noncontrolling Interests | -67.64 | -100.16 | -133.81 | -167.79 |
| Net Income Continuous Operations | -67.64 | -100.16 | -133.81 | -167.79 |
| Net Non Operating Interest Income Expense | 4.02 | 14.19 | 25.02 | 23.61 |
| Interest Income Non Operating | 4.02 | 14.19 | 25.02 | 23.61 |
| General And Administrative Expense | 17.63 | 23.45 | 31.87 | 40.02 |
| Other Gand A | 17.63 | 23.45 | 31.87 | 40.02 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Edgewise Therapeutics, Inc.this co. | EWTX | $3.3B | - | 6.20 | -32.1% | -14.47 |
| Twist Bioscience Corporation | TWST | $3.5B | - | 7.62 | -16.4% | -30.08 |
| Oruka Therapeutics, Inc. | ORKA | $3.4B | - | 7.07 | -22.5% | -24.94 |
| Liquidia Corporation | LQDA | $3.4B | - | 74.37 | -154.0% | -66.91 |
| Brookdale Senior Living Inc. | BKD | $3.4B |
| - |
| -74.95 |
| 605.6% |
| 18.66 |
| LivaNova PLC | LIVN | $3.2B | - | 2.68 | -20.2% | 11.72 |
| Tango Therapeutics, Inc. | TNGX | $3.2B | - | 8.66 | -29.3% | -26.04 |
| Beam Therapeutics Inc. | BEAM | $3.0B | - | 2.35 | -6.5% | -5.05 |
| Denali Therapeutics Inc. | DNLI | $3.0B | - | 2.87 | -50.6% | -3.93 |
| Peer Median | - | - | 4.97 | -21.3% | -15.00 | |